# Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

> **NCT00591123** · PHASE2 · COMPLETED · sponsor: **Translational Oncology Research International** · enrollment: 38 (actual)

## Conditions studied

- Unresectable Adenocarcinoma of the Esophagus
- Metastatic Adenocarcinoma of the Esophagus
- Unresectable Adenocarcinoma of Gastric Cardia
- Metastatic Adenocarcinoma of Gastric Cardia

## Interventions

- **DRUG:** FOLFOX
- **DRUG:** 5-FU
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00591123
- **Lead sponsor:** Translational Oncology Research International
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-06
- **Final completion:** 2015-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00591123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00591123, "Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00591123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*